<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3204345/" ref="ordinalpos=4380&amp;ncbi_uid=3314084&amp;link_uid=PMC3204345" image-link="/pmc/articles/PMC3204345/figure/fig5/" class="imagepopup">Fig. 5. From: Smad phosphoisoform <span class="highlight" style="background-color:">signaling</span> specificity: the right place at the right time. </a></div><br /><div class="p4l_captionBody">Cell type-specific temporal dynamics of R-Smad phosphoisoforms. Although linker phosphorylation is transient after mitogen treatment of normal epithelial cells (<b>A</b>), mitogen-inducible phosphorylation generally persists in various mesenchymal cells (<b>B</b>). Moreover, constitutive linker phosphorylation is found in almost all types of carcinomas and Ras-transformed cells (<b>C</b>). Because mitogenic pSmad3L signaling is followed by the cytostatic pSmad3C signaling in normal epithelial homeostasis, pSmad2L/C and pSmad3L/C rarely exist in normal epithelial cells (A). Resembling observations in mesenchymal cells (B), carcinomas acquire an invasive phenotype via the pSmad2L/C pathway created by a combination of TGF-Î² signal with intracellular Ras signal (C).</div></div>